Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP4070 Phase 1 in Cedar Pollinosis
NCT02469688Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2015
- Primary completion
- Nov 2015
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ASP4070 in Japanese cedar pollinosis (10 arms), sponsored by Astellas Pharma. Primary endpoint: Adverse events developed after the first vaccination at Day 127. Started Jun 2015; status: completed.
02
Drugs
ASP4070
03
Conditions
Japanese cedar pollinosis
Beyond the preview
Go deeper on NCT02469688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02469688.